Indian Colorectal Cancer drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
CRC rates are rising in India. Even though the absolute rates are low in the Indian population, the rising rates pose a problem in rising cancer morbidity in India. The rising rates can be attributed to changing lifestyles that include consumption of calorie-rich and low fibre diet, excessive use of red meat and processed foods, and physical inactivity. There is a need for cost-effective strategies to enable early diagnosis for colorectal cancer in India. Affordable and equitable treatment will help increase the 5-year survival rates of colorectal cancers. The incidence in urban areas was higher than that in rural areas, and was higher in more economically developed areas, with a recent rapid increase in the southeast coastal region of India.
Increasing prevalence of colorectal cancer owing to the unhealthy food habits, increasing use of biologics. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective. These factors add to the risk of an individual to growth of tumours that would lead to cancer. Increasing geriatric population base and growing number of clinical trials to market new drugs is set to further enhance the overall market demand of colorectal cancer during the forecast period. Also, it is mainly driven by factors such as rise in pipeline colorectal cancer screening test, increasing awareness and government policies to provide better care for colorectal cancer.